KR900013969A - Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea - Google Patents

Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea Download PDF

Info

Publication number
KR900013969A
KR900013969A KR1019900003230A KR900003230A KR900013969A KR 900013969 A KR900013969 A KR 900013969A KR 1019900003230 A KR1019900003230 A KR 1019900003230A KR 900003230 A KR900003230 A KR 900003230A KR 900013969 A KR900013969 A KR 900013969A
Authority
KR
South Korea
Prior art keywords
active ingredient
methylthioadenosine
adenosylmethionine
weight
deoxy
Prior art date
Application number
KR1019900003230A
Other languages
Korean (ko)
Inventor
매기오니 모라티 에마누엘라
Original Assignee
원본미기재
바이오리써치 에스. 피. 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 바이오리써치 에스. 피. 에이 filed Critical 원본미기재
Publication of KR900013969A publication Critical patent/KR900013969A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/008—Preparations for oily hair
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

내용 없음No content

Description

지루를 감소시키는 약학 조성물의 제조에 있어서 5'0데옥시-5'-메틸티오아데노신, S-아데노실메티오닌 및 이들의 염의 용도 및 이와 관련된 약학 조성물Use of 5'0deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 지루환자에 MTA 및 위약을 경구투여 하기 전과 후의 평균 피지 측정값의 히스토그램 비교도이다.1 is a histogram comparison of mean sebum measurements before and after oral administration of MTA and placebo to seborrheic patients.

제2도는 환자에 MTA 및 위약을 경구투여하기 전과 후의 모발 및 두피의 기름기에 대한 측정값의 히스토그램 비교도이다.FIG. 2 is a histogram comparison of measurements of grease in hair and scalp before and after oral administration of MTA and placebo to a patient.

제3도는 환자에 MTA 및 위약을 경구투여하기 전과 후의 비듬에 대한 측정값의 히스토그램 비교도이다.FIG. 3 is a histogram comparison of measurements for dandruff before and after oral administration of MTA and placebo to a patient.

Claims (23)

두피 지루 및 이와 관련된 강상 낙설 및 소양증을 감소시킬 수 있는 약학 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, S-아데노실메티오닌 및 약학적으로 허용되는 이들의 염의 용도.Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and pharmaceutically acceptable salts thereof in the manufacture of a pharmaceutical composition capable of reducing scalp seborrhea and associated erosion and pruritus. 제1항에 있어서, 약학 조성물의 경구투여에 적합한 용도.The use according to claim 1 suitable for oral administration of the pharmaceutical composition. 제1항에 있어서, 약학 조성물의 비경구 투여에 적합한 온도.The temperature of claim 1 suitable for parenteral administration of the pharmaceutical composition. 제2항에 있어서, 사용된 활성 성분의 양이 50내지 1600㎎인 용도.Use according to claim 2, wherein the amount of active ingredient used is 50 to 1600 mg. 제4항에 있어서, 사용된 활성 성분의 양이 바람직하게는 600 내지 1200㎎인 용도.5. Use according to claim 4, wherein the amount of active ingredient used is preferably 600 to 1200 mg. 제1항에 있어서, 약학 조성물이 국부투여에 적합한 온도.The temperature of claim 1, wherein the pharmaceutical composition is suitable for topical administration. 제6항에 있어서, 활성성분이 5'-데옥시-5'-메틸티오아데노신인 경우에는 용액의 0.1 내지 5중량%의 양으로 사용되고 S-아데노실메티오닌인 경우에는 용액의 0.2 내지 16중량%의 양으로 사용되는 용도.The method according to claim 6, wherein the active ingredient is 5'-deoxy-5'-methylthioadenosine and is used in an amount of 0.1 to 5% by weight of the solution, and 0.2 to 16% by weight of the solution if S-adenosylmethionine. Use in amounts of. 제7항에 있어서, 활성 성분이 5'-데옥시-5'-메틸티오아데노신인 경우에는 바람직하게는 용액의 0.25내지 2중량의 양으로 사용되고 S-아데노실메티오닌인 경우에는 바람직하게는 용액의 2 내지 8중량%의 양으로 사용되는 용도.The method according to claim 7, wherein the active ingredient is 5'-deoxy-5'-methylthioadenosine, preferably in an amount of 0.25 to 2 weight of the solution, and in the case of S-adenosylmethionine, preferably Use in amounts of 2 to 8% by weight. 활성 성분으로 5'-데옥시-5'-메틸티오아데노신, S-아데노실메티오닌 또는 약학적으로 허용되는 이들의 염을 함유함을 특징으로 하는, 두피 지루 및 이와 관련된 강상 낙설 및 소양증을 감소시킬 수 있는 약학 조성물.It is characterized by containing 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine, or a pharmaceutically acceptable salt thereof as an active ingredient, which reduces scalp seborrhea and associated flatulence and pruritus. Pharmaceutical compositions that may be present. 제9항에 있어서, 경구투여에 적합한 약학 조성물.A pharmaceutical composition according to claim 9 suitable for oral administration. 제9항에 있어서, 비경구투여에 적합한 약학 조성물.10. A pharmaceutical composition according to claim 9 suitable for parenteral administration. 제10항 또는 제11항에 있어서, 활성 성분의 함량이 50 내지 1600㎎인 약학 조성물.The pharmaceutical composition according to claim 10 or 11, wherein the content of the active ingredient is 50 to 1600 mg. 제12항에 있어서, 활성 성분의 함량이 바람직하게는 600 내지 1200㎎인 약학 조성물.The pharmaceutical composition according to claim 12, wherein the content of the active ingredient is preferably 600 to 1200 mg. 제9항에 있어서, 국부투여에 적합한 약학 조성물.A pharmaceutical composition according to claim 9 suitable for topical administration. 제14항에 있어서, 활성 성분의 함량이 5'-데옥시-5'-메틸티오아데노신의 경우에는 용액의 0.1 내지 5중량%이고 S-아데노실메티오닌의 경우에는 용액의 0.2 내지 16중량%인 약학 조성물.15. The method of claim 14 wherein the content of the active ingredient is from 0.1 to 5% by weight of the solution for 5'-deoxy-5'-methylthioadenosine and from 0.2 to 16% by weight of the solution for S-adenosylmethionine. Pharmaceutical composition. 제15항에 있어서, 활성 성분의 함량이 5'-데옥시-5'-메틸티오아데노신의 경우에는 바람직하게는 용액의 0.25 내지 2중량%이고 S-아데노실메티오닌의 경우에는 용액의 2 내지 8중량%인 방법.The method according to claim 15, wherein the content of the active ingredient is preferably 0.25 to 2% by weight of the solution for 5'-deoxy-5'-methylthioadenosine and 2 to 8% of the solution for S-adenosylmethionine. Weight percent. 활성 성분으로서 5'-데옥시-5'-메틸티오아데노신, S-아데노실메티오닌 또는 약학적으로 허용되는 이들의 염을 함유하는 약학 조성물을 투여함을 특징으로 하여, 두피 지루 및 이와 관련된 강상 낙설 및 소야증을 감소시키기 위한 치료방법.Characterized by administering a pharmaceutical composition containing 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine, or a pharmaceutically acceptable salt thereof as the active ingredient, to treat seborrheic seborrhea and associated upsets And a method for reducing pruritus. 제17항에 있어서, 투여방법이 경구투여 또는 비경구 투여인 치료방법.The method of claim 17, wherein the method of administration is oral or parenteral administration. 제18항에 있어서, 활성 성분의 함량이 50 내지 1600㎎인 치료방법.The method of claim 18, wherein the amount of active ingredient is 50 to 1600 mg. 제19항에 있어서, 활성 성분의 함량이 바람직하게는 600 내지 1200㎎인 치료방법.The method of claim 19, wherein the content of the active ingredient is preferably 600 to 1200 mg. 제17항에 있어서, 투여방법이 국부투여인 치료방법.The method of claim 17, wherein the method of administration is topical administration. 제21항에 있어서, 활성 성분의 함량이 5'-데옥시-5'-메틸티오아데노신의 경우에는 용액의 0.1 내지 5중량%이고, S-아데노실메티오닌의 경우에는 용액의 0.2 내지 16중량%인 치료방법.The active ingredient content of claim 21 wherein the content of the active ingredient is from 0.1 to 5% by weight of the solution for 5'-deoxy-5'-methylthioadenosine and from 0.2 to 16% by weight of the solution for S-adenosylmethionine. Phosphorus treatment. 제 22항에 있어서 활성 성분의 함량이 5'-데옥시-5'-메틸티오아데노신의 경우에는 바람직하게는 용액의 0.25 내지 2중량%이고 S-아데노실메티오닌의 경우에는 바람직하게는 용액의 2 내지 8중량%인 치료방법.The active ingredient content according to claim 22 is preferably 0.25 to 2% by weight of the solution in the case of 5'-deoxy-5'-methylthioadenosine and preferably in the case of S-adenosylmethionine. To 8% by weight. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900003230A 1989-03-13 1990-03-12 Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea KR900013969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19737A/89 1989-03-13
IT8919737A IT1229477B (en) 1989-03-13 1989-03-13 USE OF 5 'DEOXY - 5' METHYLTHIOADENOSINE, S ADENOSYLMETHIONINE AND THEIR SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO REDUCE SEBORRHEA AND RELATED PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
KR900013969A true KR900013969A (en) 1990-10-22

Family

ID=11160803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900003230A KR900013969A (en) 1989-03-13 1990-03-12 Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea

Country Status (11)

Country Link
US (1) US5753213A (en)
EP (1) EP0387756B1 (en)
JP (1) JPH0778011B2 (en)
KR (1) KR900013969A (en)
AT (1) ATE99945T1 (en)
CA (1) CA2012046C (en)
DE (1) DE69005860T2 (en)
DK (1) DK0387756T3 (en)
ES (1) ES2062137T3 (en)
IT (1) IT1229477B (en)
ZA (1) ZA901929B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247903B (en) * 1991-02-25 1995-01-05 Bioresearch Spa USE OF S-ADENOSYL-METHIONINE IN THE TREATMENT OF INTRAHEPATIC CHOLESTASIS FROM TOTAL PARENTERAL NUTRITION
KR100309141B1 (en) * 1998-04-13 2001-12-28 조영동 Immunoassay using 5'-deoxy-5'-methylthioadenosine
DE10132338A1 (en) * 2001-07-04 2003-01-16 Basf Ag Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic products
ITMI20012462A1 (en) * 2001-11-22 2003-05-22 Gnosis Srl PROCESS FOR THE PREPARATION OF TABS INCLUDING S-ADENOSYLMETHIONINE
ITMI20032393A1 (en) * 2003-12-05 2005-06-06 Applied Pharma Res COMPOSITIONS CONTAINING METHYLIOADENOSINE-MTA-AND THEIR TOPICAL USE.
US7406746B2 (en) * 2004-08-31 2008-08-05 Bushey Richard D Slider for heavy loads
FR2884421B1 (en) 2005-04-15 2007-08-10 Virbac Sa NEW MEANS FOR CONTROLLING BEHAVIORAL DISORDERS IN PETS
EP2151498A3 (en) * 2005-04-20 2010-12-15 BASF Plant Science GmbH Expression cassettes for seed-preferential expression in plants
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20080206333A1 (en) * 2007-01-31 2008-08-28 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20100062993A1 (en) * 2008-09-11 2010-03-11 Yochanan R. Bulka Adenosine Nucleotides as Dietary Supplements and as Agents in the Prevention of Cancer and the Metastasis Thereof
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2014163152A1 (en) * 2013-04-05 2014-10-09 ライオン株式会社 Non-rem sleep-promoting agent, deep sleep-promoting agent and natural sleep-inducing agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7469B (en) * 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with-c-amp analogs
AR221676A1 (en) * 1974-07-12 1981-03-13 Bioresearch Sas PROCEDURE FOR THE PREPARATION OF SULPHONIC AND / OR SULFURIC STABLE SALTS OF S-ADENOSIL-L-METIONINE, PARTICULARLY USEFUL AS SPECIFIC METHYL DONORS FOR THE CH3, ELAMIBLI-TRANSFERRING BIOCHEMICAL AND LATIN-GLOBAL ELEMENTS PROTILICO AND GLUCIDICO
US4496588A (en) * 1977-07-11 1985-01-29 Merrell Toraude Et Compagnie Method of treating psoriasis
US4373097A (en) * 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
IT1137640B (en) * 1981-08-24 1986-09-10 Bioresearch Srl STABLE SALTS OF S-ADENOSYLMETHIONINE, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT INCLUDE THEM AS AN ACTIVE PRINCIPLE
JPS59134710A (en) * 1983-01-21 1984-08-02 Suntory Ltd Hair tonic from fermentation product
FR2580478B1 (en) * 1985-04-17 1989-05-12 Christian Chapoton HAIR TREATMENT DEVICE RELEASING ACTIVE SUBSTANCE AND MANUFACTURING METHOD
EP0216357A3 (en) * 1985-09-25 1988-08-31 Nippon Zeon Co., Ltd. Phosphoramidite compounds and process for production thereof
GB8607265D0 (en) * 1986-03-24 1986-04-30 London King S College Protecting groups of organic synthesis
ATE87932T1 (en) * 1986-12-02 1993-04-15 Centre Nat Rech Scient ALPHA OLIGONUCLEOTIDES.
FR2623396B1 (en) * 1987-11-25 1990-03-30 Sanofi Sa USE OF ADEMETIONINE AGAINST AGING SKIN

Also Published As

Publication number Publication date
IT8919737A0 (en) 1989-03-13
ATE99945T1 (en) 1994-01-15
EP0387756A1 (en) 1990-09-19
DE69005860D1 (en) 1994-02-24
ZA901929B (en) 1990-12-28
US5753213A (en) 1998-05-19
DK0387756T3 (en) 1994-03-07
JPH0368520A (en) 1991-03-25
CA2012046A1 (en) 1990-09-13
EP0387756B1 (en) 1994-01-12
ES2062137T3 (en) 1994-12-16
JPH0778011B2 (en) 1995-08-23
DE69005860T2 (en) 1994-04-28
CA2012046C (en) 2001-02-13
IT1229477B (en) 1991-09-03

Similar Documents

Publication Publication Date Title
CA1157380A (en) Preparations containing methylsulfonylmethane and methods of use and purification
KR900013969A (en) Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea
US4477469A (en) Preparations containing methylsulfonylmethane and methods of use and purification
KR900701282A (en) Treatment, prevention of ischemic diseases of the heart or brain
KR920000324A (en) Essential Fatty Acid Treatment
KR920007629A (en) A pharmaceutical composition exhibiting activity in the treatment of neurological diseases of AIDS patients by containing at least one compound selected from SALMe salt, 5-MTHF and 5-FTHF as an active ingredient.
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
JP2937446B2 (en) Blackening agent to prevent gray hair
KR960000855A (en) L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same
BR112019001081B1 (en) TOPICAL COMPOSITION AND USES OF COMPOSITION
KR970061244A (en) Pharmaceutical composition for treating dementia
CA2086565A1 (en) Pharmaceutical composition for treating pigmentation
US4034114A (en) Treatment of skin keratoses with retinal
KR900013935A (en) Use and pharmaceutical compositions of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof in the preparation of hair growth promoting pharmaceutical compositions
FR2712809B1 (en) New pharmaceutical composition intended for the preparation of a stable powder containing, as active ingredient, a combination of acetylsalicylic acid and metoclopramide.
KR940013503A (en) Pharmaceutical compositions for the prevention or treatment of atherosclerosis
US4520132A (en) Use of undecylenic acid to treat herpes labialis
US4438129A (en) Use of clotrimazole to treat herpes labialis
JP2709513B2 (en) Hair restoration
US4714703A (en) Method of inhibiting herpetic lesions
EP1150671B1 (en) Use of pyrethroid compounds to promote hair growth
JP2000198718A (en) External preparation for promoting blood circulation
USRE32990E (en) Use of undercylenic acid to treat herpes labialis
CA1207238A (en) Use of haloprogin in the treatment of herpes labialis
JPS63313715A (en) Hair growth stimulating composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application